Repeat visitors to this site may find it useful to have an overview of changes and updates made since their last visit. Here is where to find that information.
For discussion, view the companion site to this site called our brain tumor cocktails and stories
Astrocytoma Options update mailing list: Would you like to receive email notification of updates added to this page? Send me your email address via the comments box at the bottom of this page or email me directly at email@example.com and I will add you to the updates mailing list (by blind carbon copy). You can also unsubscribe the same way you signed up (leave a message in the text box below, or email me).
Checklist for the Newly Diagnosed, available at VirtualTrials.com (posted April 3, 2015)
February 4 ~ Find a summary on the Exploring Strategies for IDH1 Mutated Gliomas page of a new study showing increased sensitivity in IDH1 mutant cells to approved PARP inhibitors
November 26 ~ The Exploring Strategies for IDH Mutated Gliomas page was updated with a section called IDH1-mutant cells are highly vulnerable to NAD+ depletion via pharmacological inhibition of NAMPT
Clinical highlights from the 2016 annual SNO meeting have been summarized on the SNO 2016 Clinical Highlights page. Further insights from the conference will be added separately to pages on this site.
September 25 ~ The Genetic Overview of Astrocytomas page was updated with a summary of a new study on the importance of copy number-neutral loss of heterozygosity of chromosome 17p, which contains the TP53 gene.
September 2 ~ Re-Educating the Immune System was updated with new evidence concerning the effects of met-enkephalin on microglia. Met-enkaphalin is one of the main endogenous opioids increased following transient opioid receptor blockade by low dose naltrexone. This new summary is found under the sub-section on Low Dose Naltrexone.
August 30 ~ The Standard of Care page was updated with sections on temozolomide for low grade gliomas, including data from the phase 3 EORTC 22033-26033 trial, and the newly published phase 2 trial at UCSF.
August 26 ~ Find the 2016 edition of Ben Williams’ annual Treatment Options for Glioblastoma and Other Gliomas document now published at Virtualtrials.com.
July 16 ~ An important new in vivo study combining a lysate-pulsed dendritic cell vaccine with PD-1 antibody in the GL261 mouse glioma model has been summarized on the Immunotherapy page, under the section heading “PD-1 ANTIBODIES (NIVOLUMAB AND PEMBROLIZUMAB)”.
February 23 ~ The film we’ve all been waiting for is now available. Surviving Terminal Cancer, by film-maker Dominic Hill, recently premiered in London and New York and is now available for free viewing. The film features 3 long-term brain tumour survivors (Ben Williams, Rich Gerber, and Anders Ferry), and multiple other commentators. Over the past 4 months I’ve been volunteering with an international group designing a clinical trial protocol to test the strategy described in this film – a multi-agent “cocktail” of repurposed drugs for newly diagnosed glioblastoma. Watch the full-length film at the survivingterminalcancer.com website.
November 20 ~ Astrocytoma Options is launched.